Chiasma Inc. (NASDAQ:CHMA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Shares of Chiasma (NASDAQ:CHMA) opened at 2.85 on Tuesday. The stock’s market capitalization is $69.41 million. Chiasma has a 52 week low of $2.40 and a 52 week high of $24.78. The firm’s 50-day moving average price is $2.76 and its 200 day moving average price is $3.69.
Chiasma (NASDAQ:CHMA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.47. Analysts expect that Chiasma will post ($3.14) earnings per share for the current year.
Several hedge funds have recently made changes to their positions in CHMA. MPM Asset Management LLC raised its stake in shares of Chiasma by 1.0% in the second quarter. MPM Asset Management LLC now owns 5,736,296 shares of the company’s stock worth $16,578,000 after buying an additional 54,752 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Chiasma by 1,074.0% in the first quarter. Wellington Management Group LLP now owns 1,245,265 shares of the company’s stock worth $11,406,000 after buying an additional 1,139,195 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Chiasma by 32.5% in the first quarter. Franklin Resources Inc. now owns 807,440 shares of the company’s stock worth $7,396,000 after buying an additional 198,200 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock worth $1,233,000 after buying an additional 87,259 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Chiasma during the first quarter worth about $2,113,000. Hedge funds and other institutional investors own 58.76% of the company’s stock.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.